ACRV earnings analysis
What we found in ACRV's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Acrivon remains a clinical-stage biotechnology company with no approved products or product-sales revenue and substantial ongoing losses, including a $37.0 million six-month net loss and a $311.9 million accumulated deficit. Liquidity is a relative positive: $90.0 million of cash, cash equivalents and investments is expected to fund operations into Q4 2027, although management acknowledges the estimate could prove inaccurate. The supplied filing states that there were no material changes to the risk factors from the 2025 Form 10-K; the principal risks remain continued losses, the need for additional financing, clinical-development execution and potential share-sale overhang.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Liquidity Extends Runway to Q4 2027
- Cash, cash equivalents and investments totaled $90.0 million as of June 30, 2026. Management believes this liquidity will fund operating expenses and capital expenditures into the fourth quarter of 2027.
- Six-Month Net Loss Improved
- Net loss was $37.0 million for the six months ended June 30, 2026, versus $40.7 million in the comparable 2025 period, an improvement of $3.7 million or approximately 9%.
- Management Provides Cash Runway View
- Management expects existing liquidity to support operations into Q4 2027, although the estimate is based on assumptions that may prove incorrect and capital could be exhausted sooner.
- No Material Control Changes
- Disclosure controls and procedures were concluded to be effective at the reasonable assurance level as of June 30, 2026, with no material internal-control changes during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Persistent Losses and No Product Revenue
- The company reported a $37.0 million net loss for the six months ended June 30, 2026 and an accumulated deficit of $311.9 million as of June 30, 2026. Management expects significant expenses and operating losses over the next several years.
- Future Financing Required
- The company had $90.0 million of cash, cash equivalents and investments as of June 30, 2026, but states it will require additional capital to achieve its objectives and that available funding may not be timely, favorable or sufficient.
- Potential Share-Resale Overhang
- Acrivon had 42,853,362 common shares outstanding as of August 7, 2026, including approximately 20.8 million shares held by affiliates that are generally restricted from immediate resale. The filing warns that future sales or perceived sales could significantly reduce the share price.
- Clinical and Regulatory Execution Risk
- The company has no products approved for commercialization and has never generated revenue from product sales. All drug candidates remain in clinical or preclinical development, creating substantial clinical, regulatory and commercialization risk.
- Registered Resale and Dilution Risk
- The company registered for resale 8,235,000 common shares issued in the April 2024 private placement and 7,060,000 shares issuable upon exercise of pre-funded warrants, potentially increasing dilution and market supply.
What they said about what is next.
No numeric revenue or EPS guidance is provided in the supplied 10-Q text. Management states that existing cash, cash equivalents and investments of $90.0 million as of June 30, 2026 are expected to fund operating expenses and capital expenditures into the fourth quarter of 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Acrivon Therapeutics reported a Q1 2026 net loss of $19.0 million, a slight improvement from the $19.7 million loss in Q1 2025. While R&D expenses remained consistent at $15.2 million, G&A expenses declined…
- 10-K · March 19, 2026
- Acrivon (ACRV) is a clinical-stage precision oncology company centered on its AP3 proteomics platform and OncoSignature companion diagnostic. The company reported meaningful interim efficacy for ACR-368 in endometrial…
- 10-Q · November 13, 2025
- Acrivon reported an improved quarterly loss per share of $(0.47) in Q3 2025 versus $(0.59) in Q3 2024, driven by lower operating expenses (Q3 operating expense $19,687 vs $25,140). The company remains pre-revenue (no…
- 10-K · March 27, 2025
- Acrivon positions itself as a precision‑oncology company centered on its AP3 Generative Phosphoproteomics platform and drug‑tailored OncoSignature companion diagnostics. The 10‑K highlights meaningful clinical progress:…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ACRV makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever